Some stocks get punished because the story breaks. Others get punished because expectations got too hot and then the market suddenly remembered how to be grumpy. This setup looks a lot more like the second one. The chart is still rough, but the underlying business is doing enough right that this one may be getting more interesting again.
Inside the Conversation (Sponsored)
During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.
As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:
April 20, 2026. Circle it on your calendar.
I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens.
This is your invitation to the biggest wealth-building event of the decade.
Click Here to See how to Get Your "SpaceX Access Code"
What Just Happened
The stock got smacked, but not because the business fell apart
GeneDx Holdings Corp. (NASDAQ: WGS) has had a rough ride. The stock is down sharply from its highs and got hit hard earlier this year after investors decided 2026 guidance was not exciting enough, even though the company still projected revenue of $540 million to $555 million, or 26% to 30% growth, along with 33% to 35% growth in exome and genome revenue.
That is the kind of reaction you usually get when expectations were dressed for a parade.
The last reported numbers were still strong
The more useful part of the story is that GeneDx’s core business kept moving. In fourth-quarter 2025, revenue reached $121.0 million, up 27% year over year, while exome and genome test revenue rose 32%. Exome and genome test volume climbed 34.3%, adjusted gross margin held at 71%, and the company posted positive adjusted net income of $4.4 million.
Full-year 2025 revenue rose 41% to $427.5 million, with exome and genome revenue up 54%. Those are not exactly collapse numbers.
There is a near-term checkpoint coming
The next major date to watch is April 29, when GeneDx is expected to report first-quarter 2026 results. That gives investors a pretty quick chance to see whether the company is still tracking toward the growth story management laid out earlier in the year.
Why The Business Matters
This is a genomics story, not just a lab test story
GeneDx focuses on exome and genome testing, which puts it in a much more specialized lane than a generic diagnostics company.
The pitch is that as genomics becomes a more accepted frontline diagnostic tool, especially in pediatrics and rare disease settings, GeneDx has a chance to keep gaining share in a market that still looks underpenetrated.
The core engine has been the right one
The key thing here is that exome and genome testing is where the momentum lives. That business has been growing much faster than the broader company, and it carries the kind of margins investors actually want to see.
Management is still guiding to at least 70% adjusted gross margin for 2026, which is a very helpful trait for a company trying to convince the market that this is not just a top-line science project.
There is also a data angle here
The longer-term appeal is not only the tests themselves. Companies in genomics often get more valuable when they accumulate data, improve interpretation, and become more embedded in clinical decision-making.
That is part of why this remains a higher-upside story than a standard healthcare services stock, even if it also comes with more drama.
If you could have bought one stock at IPO and held it to today, which would you pick?
History Repeating Itself (Sponsored)
On August 15, 1971, Richard Nixon ended the gold standard—changing the value behind every dollar overnight.
Those who acted early positioned themselves ahead of a major shift, while others felt the impact over time.
Today, new discussions around monetary policy are drawing renewed attention from investors.
The 2026 Gold Guide explains what happened—and why it still matters.
Why The Stock Still Has A Case
Growth is still very real
The cleanest bull argument is that the core business is still growing fast enough to matter. A company that just posted 41% full-year revenue growth, 54% exome and genome revenue growth, and 34% fourth-quarter exome and genome volume growth is not exactly limping into 2026.
The margins are better than people may assume
GeneDx is also not just chasing volume for the sake of it. The company’s adjusted gross margin held at 71% in both the quarter and full year, and it exited 2025 with expectations for positive adjusted net income in 2026. That makes the setup easier to support than the usual high-growth healthcare name that asks investors to ignore profitability until sometime after retirement.
The smart-money curiosity is not dead
Another thing worth noticing is that Cathie Wood’s ARK has been buying more GeneDx shares in April. That does not prove the stock is about to fly, but it does tell you at least one very aggressive growth investor thinks the selloff has made the setup more attractive, not less.
The upside case is still getting talked about
Analyst targets and valuation takes are all over the place, which usually means one thing: this is still a stock people can argue about. Some analysts remain very bullish, while broader valuation narratives continue to paint the shares as deeply discounted after the recent slide. That kind of disagreement can be messy, but it is also how outsized rebounds sometimes begin.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
Why It Works Still Work From Here
Expectations have already been reset
This may be the most important part. The stock has already been punished for guidance that was good but not flashy enough. Once that happens, the bar tends to come down. GeneDx no longer needs to look perfect. It just needs to keep showing that the core exome and genome story is tracking well and that profitability is moving in the right direction.
The company still has room to surprise
If first-quarter results show strong volume, stable pricing, and continued margin discipline, the stock will look very different from how it looks now. This is one of those names where sentiment has become soft enough that simply being solid may go a long way.
The setup is still tied to a real long-term trend
Genomics adoption is still a legitimate structural theme. If GeneDx keeps building in pediatrics, NICU, and adjacent specialties, the runway may be a lot longer than the market has patience for right now. That is often where the more interesting healthcare growth stories hide.
Triple Your Money (Sponsored)
Early users could have already tripled their money every single year this AI has been live, based on the average winning trade spotted - WITHOUT having to check the news, WITHOUT watching the Fed, and WITHOUT all the stress most traders have to deal with.
For now, you can try this AI yourself, completely free of charge – no email, no credit card.
The Risks Around The Corner
Guidance disappointment is still fresh
The market already showed that it is not in a forgiving mood here. If management misses the next step or sounds even a little wobbly on the call, investors may not be eager to hand out second chances.
Reimbursement still matters a lot
This is one of the bigger risks in the whole story. The bull case depends heavily on supportive reimbursement trends and continued payer acceptance, especially as the company pushes deeper into broader clinical use. If reimbursement gets less friendly, the growth narrative can get dented fast.
The cash-burn debate is not gone
There is still concern around parts of the whole genome sequencing business and how efficiently that growth translates into durable profits. If investors decide the company is growing nicely but still spending too aggressively or facing too much payer friction, the stock can stay stuck in the penalty box for a while.
What I’d Watch Next
First-quarter results on April 29
This is the obvious one. Investors will want to see whether GeneDx is tracking toward its 2026 revenue and exome/genome growth goals.
Exome and genome volume growth
That is still the heartbeat of the story. If volume stays strong, the growth narrative remains very alive.
Gross margin and path to profitability
A company like this gets much more interesting when growth and profitability start playing nicely together. GeneDx has made progress there, and that trend needs to continue.
My Take
GeneDx is one of those stocks where the chart is telling a much uglier story than the business itself.
That does not make it safe. It is still a volatile healthcare growth name with real reimbursement risk, a high-expectation audience, and a market that can turn moody fast. But the core ingredients are still there: fast exome and genome growth, strong gross margins, improving profitability, and a long-term genomics adoption story that still has real legs.
The clean bull case is pretty simple. GeneDx keeps growing its core testing business, proves the 2026 guide was conservative rather than weak, and reminds investors that a stock being down a lot is not the same thing as a business being broken.
Sometimes the comeback story starts when the market gets bored right before the next good quarter.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
